Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure
-Team will focus on global NanoFlu licensure and evaluation of post-pandemic influenza/COVID-19 combination vaccine with NVX-CoV2373 -Russell (Rip) Wilson promoted to Executive Vice President and NanoFlu General Manager
... as the exploration of a combined influenza/COVID-19 vaccine that could be used in a post-pandemic setting...
wird sicher erst in 2-3 Jahren kommen, da ist die Pandemie schon vorbei und der Markt geflutet von Corona Vakzinen, aber der Markt bzw. die US Aktionäre reagieren derzeit Poitiv auf alles was von den Amerikanischen Biotechs so lanciert wird.
Erstmal muss Novavax sein Single Corona Vakzine final getestet und dann genehmigt bekommen und das dauert auch noch. Das ist ja ganz tolles Marketing aber nicht mehr, denn auch die anderen Biotechs werden in Zukunft kombinierte Grippe/Corona Impfungen anbieten, aber derzeit ist der Focus erstmal drauf überhaupt ein Corona Vakzine zu entwickeln und von den Behörden genehmigt zu bekommen. Ich finde solche News von Novavax nicht seriös, aber was tut man nicht alles um seinen Aktienkurs zu pushen und man sieht, es funktioniert in USA bei den US Aktionären ganz gut.....da kann sich Biontech und CureVac eine Scheibe abschneiden bzw. die Beiden sind einfach zu seriös um solch Zukunftsmusik zu lancieren um ihren Aktienkurs zu pushen.....Da kommt so eine News von Biontech https://www.n-tv.de/politik/...er-Impfstoff-naht-article22095146.html und der Aktienkurs bewegt sich gerade mal so um die 5% nach oben. Wenn Novavax so eine News rausgeben würde, dann würde das sicher 100% ++ Anstieg bedeuten ....;-)
Delighted to welcome Kate Bingham, head of the UK Vaccine Taskforce today who is taking part in the Novavax vaccine trial based at the Royal Free Hospital.
Aktienwelt
: Novavax VS BioNTech VS CureVax VS Moderna
Hallo zusammen =),
Novavax hat ja genauso wie BioNTech und Moderna ihren Impfstoff bereits in Phase III. Ich habe hierzu einmal ein kompaktes Video erstellt, in dem dir die Finanzen, die Produktkandidaten und der aktuelle Status samt Plan für den Covid-19-Impfstoff all dieser Unternehmen dargestellt werden. Anbei der Link:
Novavax redesigns U.K. trial to align with global COVID-19 vaccine trials
...Novavax has modified the U.K. Phase III trial of its COVID-19 vaccine candidate to ensure that it could support EMA approval and, the company believes, potentially support authorization or approval in the U.S.
...While the U.S. trial will be designed to support FDA authorization, Glenn acknowledged that the fast-moving situation, including the possibility that competing vaccines could gain authorization this year, could make it difficult to complete the trial. If that happens, he believes the U.K. trial could support U.S. authorization.
...EMA has told Novavax that the South Africa trial, which includes an arm with HIV positive participants, could potentially support European approval, he added.
" Interessanter Artikel: " ja , aber für viele Kleinanleger in meinen Augen schon etwas negativ und nicht für den Kurs förderlich hoffentlich , fallen sie nicht unter 60 Euro
... Novavax has also created a global production network to enable manufacturing and rapid distribution across the U.S., Asia and Europe if and when its COVID-19 vaccine is approved for use. The Company also reported positive Phase 3 data for its influenza vaccine candidate, NanoFlu, earlier this year...
Banani
: Novavax will supply 40 million vaccine doses
Australia signs two more COVID-19 vaccine agreements
...Under the new deals, to be announced on Wednesday, Novavax will supply 40 million vaccine doses and Pfizer/BioNTech will provide 10 million, should the vaccines be proven safe and effective through advanced clinical trials...
Banani
: Novavax and Commonwealth of Australia Announce
Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community.
‘dysfunctional’ approach to Covid-19 vaccine distribution
... He said the vaccines likely to reach the market a bit after the initial shots could have advantages. While Pfizer and Moderna have been the first companies to report early, encouraging results in late-stage clinical trials of their mRNA vaccines, Gates said the levels of antibodies elicited are much higher in more conventional vaccines being developed by Novavax and Johnson & Johnson; AstraZeneca’s comes in a little below the mRNA ones. Gates also said the cold-chain requirements and the cost of scaling up mRNA vaccine production “is not as attractive” as the other approaches.
“The fact that Novavax and J&J are above Pfizer makes us very hopeful that in the first quarter [of 2021] those vaccines will get approved and those we can make in many hundreds of millions per month in these developing world factories.”...
Thread abonnieren
